MAP2K7 and glioma: MEK inhibition has emerged recently as a targeted therapeutic approach for NF1-associated tumors [35,36], and temozolomide is a standard chemotherapeutic agent for high-grade gliomas [37] and is occasionally used to treat MPNST.